Bruce K. Patterson
25Patents
7h-index
17Co-inventors
66Inventor score
Filing activity: May 18, 1994 → Jun 16, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5843640A | Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells | Physics | 41 | Expired |
| US7524631B2 | HPV E6, E7 mRNA assay and methods of use thereof | Chemistry; Metallurgy | 35 | Expired |
| US11045546B1 | Methods of treating coronavirus infection | Emerging Cross-Sectional Technologies | 22 | Active |
| US7888032B2 | HPV E6, E7 mRNA assay and methods of use thereof | Chemistry; Metallurgy | 13 | Active |
| US6329167A | Method of testing adequacy of cells in a specimen | Physics | 10 | Expired |
| US6528278B2 | Method of testing adequacy of cells in a specimen | Physics | 7 | Expired |
| US6939687B2 | Method of testing adequacy of cells in a specimen | Physics | 7 | Expired |
| US6210875A | Process of determining the efficacy of drug treatment in HIV infected subjects | Emerging Cross-Sectional Technologies | 5 | Expired |
| US6329152A | Process for detecting low abundance RNA in intact cells | Chemistry; Metallurgy | 4 | Expired |
| US5840478A | Method of detecting amplified nucleic sequences in cells by flow cytometry | Physics | 3 | Expired |
| US8653250B2 | HPV E6, E7 MRNA assay and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US10782298B2 | Methods of detecting per cell PD-L1 expression and uses thereof | Physics | 1 | Active |
| US11180491B2 | Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc | Emerging Cross-Sectional Technologies | 1 | Active |
| US6235304A | Method of inhibition of HIV replication by leukemia inhibitory factor | Human Necessities | 1 | Expired |
| US6582901B2 | Cell specific anti-viral drug susceptibility test using tagged permissive target cells | Chemistry; Metallurgy | 1 | Expired |
| US11952373B2 | Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc | Emerging Cross-Sectional Technologies | 0 | Active |
| US11629196B2 | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions | Emerging Cross-Sectional Technologies | 0 | Active |
| US10167526B2 | Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells | Chemistry; Metallurgy | 0 | Active |
| US11402391B2 | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist | Physics | 0 | Active |
| US12298309B2 | Methods of assaying neoplastic and neoplasia-related cells and uses thereof | Physics | 0 | Active |
| US10308990B2 | Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 | Chemistry; Metallurgy | 0 | Active |
| US11726089B2 | Methods of assaying neoplastic and neoplasia-related cells and uses thereof | Physics | 0 | Active |
| US9464332B2 | HPV E6, E7 MRNA assay and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US12228580B2 | Methods of assigning a COVID pathological type based on a cytokine/chemokine panel | Physics | 0 | Active |
| US10011884B2 | Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.